689 related articles for article (PubMed ID: 12809451)
1. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche A; Schweitzer MA; Häring HU;
Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
[TBL] [Abstract][Full Text] [Related]
2. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
3. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
4. Summaries for patients. A comparison of three insulin regimens (morning glargine, bedtime glargine, or bedtime neutral protamine Hagedorn) in addition to a pill for treating type 2 diabetes.
Ann Intern Med; 2003 Jun; 138(12):I33. PubMed ID: 12809480
[No Abstract] [Full Text] [Related]
5. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
6. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
7. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
Pan CY; Sinnassamy P; Chung KD; Kim KW;
Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
[TBL] [Abstract][Full Text] [Related]
8. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
9. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
10. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility.
Standl E; Maxeiner S; Raptis S;
Horm Metab Res; 2006 Mar; 38(3):172-7. PubMed ID: 16673208
[TBL] [Abstract][Full Text] [Related]
11. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
12. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
[TBL] [Abstract][Full Text] [Related]
13. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
14. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
15. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study.
Fonseca V; Bell DS; Berger S; Thomson S; Mecca TE
Am J Med Sci; 2004 Nov; 328(5):274-80. PubMed ID: 15545844
[TBL] [Abstract][Full Text] [Related]
16. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
[TBL] [Abstract][Full Text] [Related]
17. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
18. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
20. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
Massi Benedetti M; Humburg E; Dressler A; Ziemen M
Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
